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epression is one of the most pressing public health
issues because of its high lifetime prevalence of about
15%,and because it is associated with substantial disabil-
ity.
1 Depression was the fourth leading cause of disease
burden in 2000 and accounted for 4.4% of total disability-
adjusted life years (DALY).
1 Depression is projected to be
the second leading cause of disease burden worldwide,and
the leading cause in high-income countries for DALY in
2030.
2 Depression is also responsible for the greatest pro-
portion of disease burden attributable to nonfatal health
outcomes,accounting for almost 12% of total years lived
with disability worldwide.
2 Often,depression assumes a
chronic course,and over time is associated with increasing
disability.
3,4 Furthermore,depression has been shown to be
an independent predictor of the development of cardio-
vascular disease,
5 the leading cause of death worldwide.
For all of these reasons,it is important to treat depression
aggressively.Remission,the virtual absence of symptoms,
is the aim of depression treatment because remission is
associated with better function and a better prognosis than
is response without remission.However,in clinical trials
only about one third of patients achieve remission.
6,7There
are several predictors of nonremission, among which
somatic and psychiatric comorbidity have a prominent
role.This article will shed some light on the role of somatic
and psychiatric comorbidity in incomplete remission in
depression.
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Depression is one of the most pressing public health issues,
because of its high lifetime prevalence and because it is
associated with substantial disability. In depressed
patients, psychiatric and medical comorbidity is the rule
rather than the exception. About 60% to 70% of
depressed patients have at least one, while 30% to 40%
have two or more, concurrent psychiatric disorders.
Among these, anxiety disorders and substance use disor-
ders are the most common axis I comorbidities.
Furthermore, two thirds of depressed patients have at
least one comorbid medical illness. Among depressed
patients, those with a current comorbid psychiatric condi-
tion (in particular an anxiety or substance use disorder) or
medical illness seem to have an impaired response and
remission rate during treatment compared with those
patients without comorbidity. However, in depressed
patients who all have the same comorbid condition, the
relative benefit of an antidepressant compared with
placebo appears to be equal to those effects achieved in
depressed patients without comorbidity. These findings
raise important research and treatment issues regarding
the generalizability from randomized controlled trials that
tend to exclude patients with comorbidity.
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In depressed patients,psychiatric comorbidity is the rule
rather than the exception.In the National Comorbidity
Survey replication (NCS-R),nearly three fourths (72%)
of participants with lifetime major depressive disorder also
met criteria for at least one of the other DSM-IV disorders
assessed in the NCS-R,including about 60% with anxiety
disorders and 24% with substance-use disorder.
8Another
large epidemiological study (The National Epidemiologic
Survey on Alcoholism and Related Condition,NESARC)
found that 40% of depressed patients had a comorbid anx-
iety disorder and 40% had comorbid alcohol abuse or
dependence.
9 Furthermore, in a study of 479 depressed
outpatients,64% of the patients met criteria for at least
one comorbid axis 1 disorder and 37% had two or more
psychiatric disorders.Again,anxiety disorders were the
most common comorbid condition and were present in
57% of those with any comorbid psychiatric disorder.
10A
European study from Finland (the Vantaa study) also
demonstrated that the great majority (79%) of depressed
patients suffered from one or more comorbid psychiatric
disorder,including anxiety disorders (57%) and alcohol
abuse (25%).
11
These data have recently been confirmed by the
Sequenced Alternatives to Relieve Depression (STAR*D)
study which enrolled 2876 outpatients from 23 psychiatric
and 18 primary care settings in the United States.
7 This
highly representative clinical sample of depressed outpa-
tients has revealed that depression is often chronic,severe,
and associated with substantial general medical and psy-
chiatric comorbidity.
12Two thirds of patients had at least
one other DSM-IV axis I psychiatric disorder,most often
an anxiety disorder followed by drug or alcohol abuse.In
fact, 40% of patients had more than one psychiatric
comorbidity.
Of note,personality disorders have not been assessed in
most studies. However, the NESARC study found a
comorbid personality disorder in 30% of respondents with
lifetime depression,while the Vantaa study found a comor-
bid personality disorder in 44% of depressed patients.
9,11
Therefore,psychiatric comorbidity in depression is even
much higher if one considers personality disorders.The
role of personality disorders in depression and its role in
remission will be discussed elsewhere in this issue (see the
article by Fava and Visani,p 461).
In summary,the available studies are remarkably consis-
tent with regard to comorbid axis I psychiatric disorders
in depressed patients.About 60% to 70% of depressed
patients have at least one comorbid condition,about 30%
to 40% have two or more comorbid psychiatric disorders.
Among these,anxiety disorders and alcohol abuse are the
most common comorbid conditions.
Anxiety disorders
Anxiety disorders are common among depressed patients,
representing about 50% to 60% of all psychiatric comor-
bidity.There is now some evidence to suggest that the sub-
type of anxious depression or a comorbid anxiety disorder
has a negative impact on remission rates in major depres-
sion.
In STAR*D,more than 50% fulfilled criteria of anxious
depression defined at baseline. At treatment level 1 of
STAR*D,which was monotherapy with citalopram,remis-
sion was significantly less likely (22% with anxious depres-
sion vs 33% with nonanxious depression) and took longer
to occur in anxious patients than in those with nonanxious
depression (Figure 1).
13Those patients who did not achieve
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Figure 1. Time to remission in 2876 patients in level 1 of STAR*D by anx-
ious versus nonanxious depression.
Adapted from ref 13: Fava M, Rush AJ, Alpert JE, et al. Difference in treat-
ment outcome in outpatients with anxious versus nonanxious depression:
A STAR*D report. Am J Psychiatry. 2008;165:342-351. Copyright ©
American Psychiatric Association 2008
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1 345 1 269 1 055 829 562 312 115remission could be switched to another antidepressant
(sertralin,bupropion,venlafaxine) or citalopram could be
augmented with bupropion or buspiron (treatment level
2).Again,those with anxious depression fared significantly
worse on both the switching and augmentation options
(Figure 1).
13
STAR*D is so far the largest sample to show that anxious
depression is associated with a worse treatment outcome
than nonanxious major depression.However,these results
are corroborated by several other studies demonstrating
worse outcome in anxious depression.As early as 35 years
ago,Paykel described a worse response to treatment with
amitryptiline in patients with anxious depression.
14
Furthermore,in 294 depressed outpatients,those with anx-
ious depression improved significantly less on an 8-week
treatment with fluoxetine compared with those with
nonanxious depression.
15 Also, depressed patients with
anxiety needed a longer time to recover than nonanxious
patients in a sample of 327 consecutively evaluated in- and
outpatients with unipolar depressive disorder.
16
In elderly patients,anxious depression was associated with
lower response rates to nortriptyline and was also associ-
ated with greater treatment discontinuation rates.
17
Furthermore, in a study of 157 depressed primary care
patients,patients with a comorbid anxiety disorder tended
to prematurely terminate treatment more frequently than
patients with major depression alone.
18 Depression-spe-
cific pharmacological and psychotherapeutic treatments
were effective for depressed patients with and without a
comorbid generalized anxiety disorder,although time to
recovery was longer for the former.Patients with lifetime
panic disorder showed poor recovery in response to psy-
chotherapy or pharmacotherapy.
18This was corroborated
by another primary care study,in which depressed patients
with comorbid anxiety disorder had a 44% increased risk
of persistent depression after 12 months.
19 Comorbid anx-
iety was also a strong predictor of nonresponse in a psy-
chotherapy trial of 134 female depressed outpatients
treated with interpersonal therapy.Higher levels of base-
line somatic anxiety and social functioning were the most
consistent predictors of nonresponse.
20 In the Vantaa study,
severity of depression and current comorbidity were the
two most important predictors of longer episode dura-
tion.
21 In that study,comorbidity,especially social phobia,
also predicted probability of,shorter time to,and number
of recurrences in patients with recurrent depression.
22
Finally,panic attacks were associated with longer depres-
sive episodes in a population-based study of major depres-
sive disorder in more than 5000 participants followed over
13 years,also consistent with the hypothesis that comor-
bid anxiety impairs remission in depression.
23
A slightly different research question was asked in two
meta-analyses and one pooled analysis with venlafaxine,
fluoxetine,and mirtazapine,respectively.These studies did
not assess the impact of anxiety on remission in depressed
patients with or without anxiety. Instead, these studies
examined the efficacy of antidepressants vs placebo in
depressed patients who also had a comorbid anxiety dis-
order or anxious depression.
In a pooled analysis of 19 randomized controlled trials
with 3183 patients,fluoxetine was significantly more effec-
tive than placebo in treating anxious major depression.
24
Venlafaxine was shown to be more efficacious than
placebo in a meta-analysis of six trials with 1398 patients
with anxious depression.
25 Finally,a meta-analysis of eight
randomized controlled trials in 293 patients found that
mirtazapine was superior to placebo and comparable to
amitriptyline for the treatment of patients with major
depression with symptoms of anxiety/agitation or
anxiety/somatization.
26
There are also some studies that failed to identify anxious
depression as a predictor of nonremission in depression.
In the first study,all patients suffered from chronic or dou-
ble depression.Surprisingly,this study even found a better
response in those patients with high baseline anxiety (66%
response in those with anxiety vs 54% response in those
without anxiety).
27A second study found that in a group
of 134 outpatients with major depression,those patients
with anxious depression were only slightly less likely to
respond to their first tricyclic antidepressant than patients
with nonanxious depression.When functional severity or
symptom severity was controlled for,this differential treat-
ment response did not hold.
28
In summary,the available data suggest that comorbid anx-
iety disorders and the subtype of anxious depression are
associated with a slower response and lower rates of remis-
sion in depressed patients.However,antidepressants do
not appear to differ in their relative effects compared with
placebo in depressed patients with and without anxiety.
Substance use disorders
While there are many studies examining the impact of
comorbid anxiety on treatment response in depressed
patients with and without anxiety, only a few studies
looked at the impact of comorbid substance use disorders
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large, placebo-controlled trials of antidepressants for
major depression exclude persons who have current sub-
stance use disorders.Instead,studies examining comorbid
depression and substance use disorders rather determined
the effects of depression on outcome in substance use.
The best way to treat patients with these concurrent dis-
orders has not been well established. One of the most
basic questions is whether to treat depression in the set-
ting of ongoing substance abuse.There are many pub-
lished reports of the treatment of depression in patients
who have substance-use disorders.A systematic review
and meta-analysis of antidepressant treatment of
depressed patients who have a concurrent alcohol or sub-
stance use disorder found that antidepressant treatment
had an overall modest effect on depression and a small
effect in decreasing drug or alcohol use in these patients.
29
The likelihood of finding an antidepressant effect was
higher in studies with low placebo response,consistent
with findings in antidepressant trials in depressed
patients without substance use disorders. The authors
concluded that antidepressants can be useful in these
patients if used in adequate doses and for an adequate
length of time (at least 6 weeks).The overall effect size
they found was 0.38,which is comparable with the effect
size,0.43,found in a meta-analysis of antidepressant tri-
als in depressed outpatients.
30
Only a few studies examined depressed patients with and
without comorbid substance-use disorder.One older study
found alcohol use to be a predictor of nonresponse in
depressed patients.
31 In STAR*D,about 20% of depressed
patients fulfilled criteria of drug or alcohol abuse or
dependence and presence of these disorders impaired
remission during monotherapy with citalopram.
7
In summary, there is some evidence to suggest that a
comorbid substance use disorder impairs remission in
depressed patients.With regard to treatment recommen-
dations in patients with substance abuse and comorbid
depression, a recent, thorough review
32 concluded that
there is a clear pattern of benefit in favor of antidepres-
sant drug treatment for patients who have co-occurring
major depression and substance use disorders.
Somatic comorbidity
Clinical trials of antidepressants usually exclude patients
with medical comorbidity;however,depression with med-
ical comorbidity is the norm rather than the exception
among patients who are seen in most clinical settings.
Recently, the WHO World Health Survey with 245 404
participants from 60 countries from all regions of the
world,showed that an average of between 9% and 23% of
participants with one or more chronic physical disease had
comorbid depression.
1This result was significantly higher
than the likelihood of having depression in the absence of
a chronic physical disease.
1 Depression produced the
greatest decrement in health compared with the chronic
diseases angina,arthritis,asthma,and diabetes.
Before the introduction of selective serotonin reuptake
inhibitors (SSRIs),treatment of depression in the med-
ically ill was difficult due to many contraindications for the
use of tricyclic antidepressants in medically ill depressed
patients.One study trying to recruit medically ill patients
with depression to a study with nortriptyline was halted at
the midpoint because of inadequate patient recruitment,
primarily a consequence of medical illnesses that pre-
vented more than 80% of eligible patients from participat-
ing in or completing the clinical trial.Major or minor med-
ical contraindications to the use of antidepressants were
present in over 90% of depressed patients.
33Another study
reported that only 40% of patients with medical illnesses
responded to treatment with different antidepressants.At
the time,the authors concluded that trials of antidepres-
sants in medical inpatients did not achieve the pattern of
therapeutic responses routinely characterizing compara-
ble interventions in psychiatric patients with depression.
34
However,there are now many studies demonstrating not
only good tolerability of the newer antidepressants in the
medically ill but also response and remission rates compa-
rable to depressed patients without medical illness.This
was confirmed in a recent meta-analysis including 18 stud-
ies,covering 838 patients with a range of physical diseases
(cancer 2,diabetes 1,head injury 1,heart 1,HIV 5,lung 1,
multiple sclerosis 1,renal 1,stroke 3,mixed 2).
35The results
of the meta-analysis were corroborated by newer random-
ized controlled trials in patients with coronary heart dis-
ease,
36-38 diabetes,
39 and stroke.
40
The studies above were conducted in patients who all had
a medical illness.Clinical trials of antidepressants usually
exclude patients with medical comorbidity.However,some
studies also addressed the issue of response and remission
in depressed patients with and without medical comorbid-
ity. The STAR*D study, which was designed to reflect
“real-world” conditions, confirmed that two thirds of
depressed patients had at least one concurrent general
medical condition.
12 Generally, the remission rates in
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uncomplicated, nonchronic symptomatic volunteers
enrolled in placebo-controlled,8-week,randomized con-
trolled trials with selective serotonin reuptake inhibitors.
7
Nevertheless,more general medical disorders were asso-
ciated with lower remission scores.Furthermore,in a study
with 370 depressed patients,a comorbid medical condition
was one of six risk factors for sustained nonremission of
depression over 4 years.
41 These findings are consistent
with another study in 384 depressed outpatients that were
enrolled in a 8-week open treatment with fluoxetine.
Compared with patients who achieved remission with anti-
depressant treatment,those who did not achieve remission
had significantly greater medical illness.Importantly,the
final Hamilton depression rating Scale score directly cor-
related with the total burden of medical illness.
42 However,
among those patients for whom the first antidepressant
treatment with fluoxetine failed to achieve remission and
who were randomized either to increased doses of fluox-
etine or to augmentation with lithium or desipramine,
medical illness was not associated with likelihood of remis-
sion or premature study discontinuation.
43
There also exist studies in primary care. Among 601
depressed patients treated in primary care settings with an
SSRI and followed over 9 months,physical impairment
was one of four independent predictors of nonresponse.
44
In a study of 1356 patients with major depression or dys-
thymia from 46 primary care clinics,the likelihood of hav-
ing a depressive disorder during 6- and 12-month follow-
up was higher for depressed patients with comorbid
medical disorders than for depressed patients who did not
have comorbid medical disorders.The authors concluded
that depressed patients with comorbid medical disorders
tend to have similar rates of treatment but worse depres-
sion outcomes than depressed patients without comorbid
medical illness.
45 Of note,two studies have demonstrated
that greater body weight
46 and obesity
47 predicted nonrep-
sonse and slower response to antidepressants.
However,there are also studies failing to demonstrate an
impact of medical illness on remission in depression.One
study enrolled 259 depressed subjects >60 years. After
adjusting for age,remission rates did not differ between
depressed patients with and without medical illness.
48
Another study examining the effects of duloxetine 60 mg
in 311 elderly patients with major depression with and
without medical comorbidity also failed to find an impact
of medical comorbidity on response and remission rates.
49
Another very small study with limited power (n = 31) also
demonstrated that response rates to a 12-week treatment
with bupropion did not differ statistically among those
with high and low medical comorbidity.
50 Furthermore,in
a 6-week,randomized,double-blind,placebo-controlled
trial of fluoxetine,20 mg daily in 671 outpatients older than
60 years,the number of chronic illnesses did not influence
treatment response but historical physical illness was asso-
ciated with greater fluoxetine response and lower placebo
response.
51Another study examined 92 patients with treat-
ment-resistant depression who entered a 6-week open-
label trial with nortriptyline.Medical comorbidity did not
predict treatment response.
52
One study in depressed patients >70 years examined the
effects of paroxetine and interpersonal psychotherapy in
maintenance therapy of depression once remission was
achieved.
53The impact of medical illness on recurrence was
also assessed.The study found that paroxetine was supe-
rior to placebo and psychotherapy in the maintenance
therapy of major depression in old age. Importantly,
patients with fewer and less severe coexisting medical ill-
ness received greater benefit from paroxetine as indicated
by a significant interaction between treatment with parox-
etine and baseline severity of medical illness (Figure 2).
53
These results indicate that medical illness might not only
affect remission during acute treatment with antidepres-
sants,but that it might also lead to a greater rate of recur-
rence during maintenance treatment of depression in old
age.
Patients with a greater number of and more severe con-
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Figure 2. Effect of the number and severity of concomitant medical ill-
nesses on the efficacy of maintenance therapy with paroxetine.
Reproduced from ref 53: Reynolds CF, III, Dew MA, Pollock BG, et al.
Maintenance treatment of major depression in old age. N Engl J Med.
2006;354:1130-1138. Copyright © Massachusetts Medical Society 2006
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Placebo, CIRS-G score≥10 (N=25)comitant medical illnesses,as indicated by scores of 10 or
more on the Cumulative Illness Rating Scale for
Geriatrics (CIRS-G), had higher rates of recurrent
depression and did not fare as well during treatment with
paroxetine as those with fewer and less severe concomi-
tant medical illnesses.Although both paroxetine use and
the score on the CIRS-G affected risk—main or direct
effect,P=0.004—paroxetine was more effective in pre-
venting recurrence in patients with fewer and less severe
concomitant medical illnesses—interaction effect,
P=0.03.
A direct comparison of the results of the above studies is
difficult because of the differences among studies.
However, most studies reported lower treatment
response in patients who had depression and comorbid
medical illness.Of those studies reporting no difference
in treatment outcome in patients with and without med-
ical comorbidity,two studies included only patients who
had treatment-resistant depression and had small num-
bers,thus having small power to detect a difference.In
conclusion,most studies suggest that depressed medically
ill individuals may be more treatment-refractory and may
respond slower or less well to antidepressant treatment
and have higher rates of depressive relapse in the main-
tenance phase.
54
Conclusion
In depressed patients,psychiatric and medical comorbid-
ity is the rule rather than exception.About 60% to 70%
of depressed patients have at least one comorbid psychi-
atric condition, about 30% to 40% have two or more
comorbid psychiatric disorders.Furthermore,two thirds
of depressed patients have at least one concurrent gen-
eral medical condition.
Among depressed patients,those with a current comor-
bid psychiatric condition (in particular an anxiety or sub-
stance use disorder) or medical illness seem to have an
impaired response and remission rate during treatment
compared with those patients without comorbidity.
However,in depressed patients who all have the same
comorbid condition,the relative benefit of an antidepres-
sant compared with placebo seems to be equal to those
effects achieved in depressed patients without comorbid-
ity.
These findings raise important research and treatment
issues.Currently,several studies have demonstrated that
65% to 90% of treatment-seeking depressed patients
would be excluded from a randomized controlled efficacy
trial.
55-58A comorbid psychiatric or medical condition was
among the most prominent reasons for excluding patients
while at the same time present in the vast majority of
depressed patients in clinical practice.Therefore,efficacy
trial findings may not generalize to actual practice. A
recent editorial summarizing the STAR*D results
12 sug-
gested that more broadly representative patients should
be enrolled in efficacy trials while ensuring patient safety
and internal validity.This would result in a better general-
izability of the results achieved in efficacy trials,and could
also reduce placebo response rates in these trials that have
risen during the past years.
30 ❏
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Remisión incompleta en la depresión: 
papel de la comorbilidad psiquiátrica y
somática
La depresión, por su alta prevalencia de vida y por-
que está asociada con una importante incapacidad,
es uno de los temas de salud pública más urgente.
En los pacientes depresivos la comorbilidad médica
y psiquiátrica es más la regla que la excepción.
Cerca del 60% al 70% de los pacientes depresivos
tiene simultáneamente a lo menos un trastorno psi-
quiátrico y un 30% a 40% tiene dos o más trastor-
nos. Entre estos, los trastornos de ansiedad y los
trastornos por uso de sustancias son las comorbili-
dades más comunes del eje I. Además, dos tercios
de los pacientes depresivos tienen a lo menos una
enfermedad médica comórbida. Entre los pacientes
depresivos, aquellos con una condición psiquiátrica
comórbida actual (en particular un trastorno de
ansiedad o uno por uso de sustancias) o con una
enfermedad médica parecen tener porcentajes de
respuesta y de remisión menores durante el trata-
miento en comparación con los pacientes sin
comorbilidad. Sin embargo, en todos los pacientes
depresivos que tienen la misma condición comór-
bida, el beneficio relativo de un antidepresivo en
comparación con placebo parece ser igual a los
efectos logrados en los pacientes depresivos sin
comorbilidad. Estos hallazgos promueven impor-
tantes temas de investigación y terapéutica en rela-
ción con la generalización de los ensayos randomi-
zados y controlados que tienden a excluir pacientes
con comorbilidad.   
Rémission incomplète dans la dépression :
rôle de la comorbidité psychiatrique et
somatique
La dépression est l’un des problèmes de santé
publique les plus urgents en raison de sa prévalence
élevée au cours de la vie et du handicap important
qui lui est associé. Chez les patients déprimés, la
comorbidité psychiatrique et médicale est la règle
plutôt que l’exception. Environ 60 % à 70 % des
patients déprimés en ont au moins une et 30 % à
40 % ont au moins deux troubles psychiatriques
concomitants. Parmi ceux-ci, l’anxiété et l’addiction
sont les troubles de l’axe I les plus souvent rencon-
trés. De plus, 2/3 des patients déprimés ont au
moins une maladie somatique comorbide. Pour les
patients déprimés qui souffrent d’une comorbidité
psychiatrique (en particulier un trouble anxieux ou
addictif) ou médicale, les taux de réponse et de
rémission au cours du traitement semblent dimi-
nués comparés aux taux des patients sans comorbi-
dité. Cependant, chez les patients qui ont tous la
même comorbidité, le bénéfice relatif d’un antidé-
presseur comparé au placebo semble équivalent à
celui obtenu chez les patients déprimés sans comor-
bidité. Ces résultats soulèvent des questions théra-
peutiques et de recherche importantes, les études
randomisées contrôlées ayant tendance à exclure
les patients atteints d’une pathologie comorbide.
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